STOCK TITAN

Editas Medicine Inc - EDIT STOCK NEWS

Welcome to our dedicated news page for Editas Medicine (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Editas Medicine's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Editas Medicine's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.27%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
acquisition
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.48%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.89%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.12%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
Editas Medicine Inc

Nasdaq:EDIT

EDIT Rankings

EDIT Stock Data

608.69M
73.88M
0.91%
75.61%
16.52%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About EDIT

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.